These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27764906)

  • 1. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
    Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
    Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
    Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
    Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
    Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
    Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.
    Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY
    Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
    Koizumi W; Kim YH; Fujii M; Kim HK; Imamura H; Lee KH; Hara T; Chung HC; Satoh T; Cho JY; Hosaka H; Tsuji A; Takagane A; Inokuchi M; Tanabe K; Okuno T; Ogura M; Yoshida K; Takeuchi M; Nakajima T;
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):319-28. PubMed ID: 24366758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
    Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
    Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
    Moriwaki T; Hirai S; Hironaka S; Amagai K; Soeda A; Sato M; Nihei T; Hirose M; Matsuda K; Ohkawara A; Yamaguchi T; Ozeki M; Mamiya T; Murashita T; Hyodo I
    Gastric Cancer; 2014 Apr; 17(2):354-61. PubMed ID: 23852397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
    Luo H; Yu Z; Gao H; Guan C; Xu M
    J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
    Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
    BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
    Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
    Yoon S; Yoo C; Ryu MH; Kang MJ; Ryoo BY; Park SR; Yook JH; Oh ST; Yoo MW; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):182-189. PubMed ID: 26661592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
    Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
    Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
    Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.